Oxford BioDynamics PLC Board Transition (6732A)
31 May 2019 - 4:00PM
UK Regulatory
TIDMOBD
RNS Number : 6732A
Oxford BioDynamics PLC
31 May 2019
31 May 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Board Transition
Alison Kibble steps down from OBD Board after 11 years'
service
Further to the announcement of 11 January 2019, Oxford
BioDynamics Plc (AIM: OBD), a biotechnology company focused on the
discovery and development of epigenetic biomarkers based on
regulatory genome architecture, for use within the pharmaceutical
and biotechnology industry, today announces that Alison Kibble has
today stepped down from the Board as Non-Executive Director.
Alison first joined OBD's Board in December 2007 as a
representative of the University of Oxford and since the Company's
IPO has served as Chair of the Audit Committee and as a member of
the Nomination and Remuneration Committees.
Following Alison's stepping down, membership of the
sub-committees of the Board is as follows:
Sub-committee Chair Other members
Audit committee David Holbrook Peter Pack
--------------- ------------------------
Nomination committee Stephen Diggle David Holbrook
Christian Hoyer Millar
--------------- ------------------------
Remuneration committee Peter Pack David Holbrook
--------------- ------------------------
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"On behalf of the Board I would like to thank Alison for her
many years of service to OBD. It has been a pleasure to work with
her since the Company was spun out of the University of Oxford in
2007. Alison has offered the Executive Directors consistent support
and challenge throughout her tenure as a Non-Executive Director,
benefiting the Company and its shareholders. We will miss her, and
wish her every future success."
Alison Kibble added:
"It has been a real privilege to be part of the team that has
seen OBD grow from a small company into a successful listed entity
with world-class technology and partnerships with major pharma and
institutions. I wish the Board and all the employees well as they
take the Company forward into the next exciting phase."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Advisor and Broker
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALLFSRERIIVIA
(END) Dow Jones Newswires
May 31, 2019 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024